Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Bausch Health: Clinical Trials & FDA Approval Profile

Bausch Health (Laval, CA / Bridgewater, NJ) sponsors 33 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 4 active protocols (1 recruiting now), 26 completed protocols, and 133 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.1%
Median Closed Enrollment vs National (145 pts)328 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Bausch Health
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)33
Active Pipeline (Recruiting Now)4 (1)
Completed vs Stopped Early26 / 3 (9.1%)
Median Closed Actual Enrollment328 participants
Physical Hospital Site Disclosure96.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals133 (11 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Bausch Health
Hospital Research SiteLocationShared Protocols
University Hospitals Cleveland Medical CenterCleveland, OH2
Eye Research FoundationNewport Beach, CA2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Bausch Health
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07428538Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)Phase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Bausch Health Interactive Dossier, benchmark peers in Ophthalmology and Sensory, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI